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Identification of Maxillary Factor, a Maxillary
Process±Derived Chemoattractant for Developing
Trigeminal Sensory Axons
through the analysis of trigeminal sensory axon projec-
tions to epithelial targets in the mouse. Cutaneous sen-
sory information from three distinct regions of the facial
epidermis is conveyed to the central nervous system by
the three branches (ophthalmic, maxillary, and mandibu-
Robert O'Connor and Marc Tessier-Lavigne*
Howard Hughes Medical Institute
Department of Anatomy and
Department of Biochemistry and Biophysics
University of California, San Francisco
San Francisco, California 94143 lar) of the trigeminal ganglion. Axons emerge from the
trigeminal ganglion in each of these branches and pro-
ject to target epithelia through a dense mesenchyme.
Experiments in which explanted trigeminal ganglia wereSummary
cultured with explanted maxillary or mandibular pro-
cesses showed that these processes could stimulateTrigeminal sensory axons project to several epithelial
the directed outgrowth of trigeminal sensory axons fromtargets, including those of the maxillary and mandibu-
the ganglia toward the targets, providing evidence for thelar processes. Previous studies identified a chemoat-
existence of a target-derived chemoattractant (Lums-tractant activity, termed Maxillary Factor, secreted by
den and Davies, 1983), which was named Maxillary Fac-these processes, which can attract developing trigem-
tor (Lumsden, 1988).inal axons in vitro. We report that Maxillary Factor
activity is composed of two neurotrophins, neuro- An important finding was that the activity was not due
trophin-3 (NT-3) and Brain-Derived Neurotrophic Fac- to Nerve Growth Factor (NGF). It was known that NGF
tor (BDNF), which are produced by both target epi- is produced by epithelia and that it can function as a
thelium and pathway mesenchyme and which are chemoattractant for regenerating axons (Gundersen
therefore more likely to have a trophic effect on the and Barrett, 1979). However, a role for NGF in attracting
neurons or their axons than to provide directional in- trigeminal sensory axons during their initial projections
formation, at least at initial stages of trigeminal axon was excluded by the findings that these axons are unre-
growth. Consistent with this, the initial trajectories of sponsive to NGF at those stages (Davies et al., 1981,
trigeminal sensory axons are largely or completely 1987; Davies and Lumsden, 1984; Wyatt and Davies,
normal in mice deficient in both BDNF and NT-3, indi- 1993) and that NGF is not expressed by the target tissue
cating that other cues must be sufficient for the initial until the stage at which the axons have reached their
stages of trigeminal axon guidance. targets (Davies et al., 1987). Consistent with those ob-
servations, the directed outgrowth of trigeminal sensory
Introduction axons elicited by the maxillary and mandibular pro-
cesses was not affected by antibodies to NGF when
Developing axons in the embryonic nervous system the ganglia and targets were obtained from younger
are guided by the coordinate action of attractive and embryos (i.e., at stages when the axons are beginning
repulsive guidance mechanisms (Tessier-Lavigne and to project to their targets), but it was blocked when the
Goodman, 1996). One of these mechanisms, long-range ganglia and targets were obtained from older embryos
chemoattraction, involves the guidance of axons by gra- in which the axons had already reached their targets
dients of diffusible factors secreted by the intermediate (Lumsden and Davies, 1983). These results showed that
and/or final cellular targets of these axons. Direct evi- (1) Maxillary Factor, secreted during the initial develop-
dence for the existence of such chemotropic factors ment of trigeminal axon projections, is biochemically
was originally provided by in vitro bioassays in which distinct from NGF, and (2) at later developmental stages,
the directional outgrowth of developing axons was pro- the trigeminal axons become responsive to NGF, and
moted by their target tissues when the tissues were NGF expression in the target is upregulated, possibly
presented to the axons at a distance (Lumsden and reflecting a role for NGF in regulating arborization of
Davies, 1983; Tessier-Lavigne et al., 1988; Heffner et al., sensory axons at the targets (see, for example, Diamond
1990; reviewed by Tessier-Lavigne and Placzek, 1991). et al., 1992). In later years, three relatives of NGF, the
In two cases, such bioassays were used to purify the neurotrophins Brain-Derived Neurotrophic Factor (BDNF),
molecules mediating the chemoattractant effects, lead- neurotrophin-3 (NT-3), and neurotrophin 4/5 (NT-4/5),
ing to the identification of netrin-1 as a floor plate± were identified (reviewed by Lewin and Barde, 1996).
derived chemoattractant for developing spinal commis-
However, the evidence to date has not clearly implicated
sural axons (Kennedy et al., 1994; Serafini et al., 1994)
these neurotrophins in guiding developing axons to their
and of Hepatocyte Growth Factor/Scatter Factor (HGF/
targets in vivo (reviewed by Kennedy and Tessier-Lavigne,
SF) as a limb-derived chemoattractant for spinal motor
1995; Tessier-Lavigne and Goodman, 1996).axons (Ebens et al., 1996).
To increase our understanding of chemoattractantOne of the first examples of target-derived chemoat-
mechanisms, we sought to determine the moleculartractants was provided by Lumsden and Davies (1983)
identity of Maxillary Factor, using the in vitro collagen
gel assay described previously for this factor (Lumsden
and Davies, 1983). Using this approach, we have identi-* To whom correspondence should be addressed (e-mail: marctl@
itsa.ucsf.edu). fied the neurotrophins NT-3 and BDNF as the major and
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Figure 1. Developmental Stage Dependence of Maxillary Factor Activity
Neurofilament staining (NF-M) of whole mouse embryo heads at the developmental stages relevant to primary trigeminal axon outgrowth
(stages 16±20 [A, D, G, J, and M]). Maxillary Factor assays at these stages were performed in the absence (B, E, H, K, and N) or presence
(C, F, I, L, and O) of function-blocking antibodies to NGF. As annotated at stage 18 (G±I), trigeminal sensory axons project to their epithelial
targets in three branches (ophthalmic [op], maxillary [mx], and mandibular [md]), and chemotropic activity of the maxillary process was assayed
by coculturing trigeminal ganglia (TG) and maxillary process tissue in three-dimensional collagen gel matrices for 48 hr. The resulting axonal
outgrowth was visualized by staining with the anti-neurofilament antibody NF-M. Activity in the absence of antibody (B, E, H, K, and N) reflects
both Maxillary Factor and NGF activity. Activity in the presence of anti-NGF (C, F, I, L, and O) reflects the activity of Maxillary Factor (by
definition; Lumsden and Davies, 1983). Maxillary Factor activity was first detectable at stage 16 (B and C), when the first trigeminal axons
begin to invade the maxillary and mandibular processes (A). The activity is strongest during stage 18 (G±I), as the first axons arrive at their
target epithelium, and the responsiveness and production of NGF has just begun. Activity disappears by stage 20 (M±O), when the majority
of trigeminal axons have arrived at their target epithelium; at that stage, all of the chemotropic activity of the maxillary process is due to NGF.
Scale bar, 250 mm.
minor components of this activity, respectively. Interest- course of development of the three peripheral branches
of the trigeminal ganglion (ophthalmic, maxillary, andingly, these factors are made by both the target epithe-
lium and the pathway mesenchyme of the maxillary and mandibular) in the mouse has been described in detail
(Davies and Lumsden, 1984, 1986; Theiler, 1989) and ismandibular processes. We show that the previous ob-
servation that Maxillary Factor is expressed by the epi- shown in Figures 1A, 1D, 1G, 1J, and 1M. The ganglion
first becomes discernible around embryonic day 9.5thelium but not the mesenchyme (Lumsden and Davies,
1986) likely reflects the dependence of mesenchymal (E9.5, or Theiler stage 15), and peripheral nerve fiber
outgrowth begins around E10 (stage 16). Approximatelyexpression of NT-3 on continued interaction with the
epithelium. 1200 fibers extend into the maxillary process at E10.5
(stage 17), with the first fibers reaching the target epithe-Our results show that these neurotrophins can be
chemoattractants for developing sensory axons. How- lium sometime during E11 (stage 18). Trigeminal axons
begin innervating the differentiating whisker folliclesever, their presence in both target and pathway sug-
gests that they are not likely to provide a directional cue around E13 (stages 20±21). The period of naturally oc-
curring cell death in the trigeminal ganglion also startsto instruct the initial migration into the maxillary process.
Consistent with this, the initial trajectory of trigeminal around E13.
In the assay for Maxillary Factor, trigeminal gangliaaxons to their targets in mice deficient in both NT-3 and
BDNF is apparently normal, although the possibility of explanted from embryos of stages 16±20 are cultured
in three-dimensional collagen gel matrices together withtargeting errors at later stages is not excluded. The
widespread distribution of NT-3 and BDNF may reflect explants of either the target maxillary process or the
target mandibular process taken from the same stagea trophic role for these factors, for which evidence has
already been provided (reviewed by Reichardt and Fari- (Lumsden and Davies, 1983). We have focused most of
our studies on guidance to the maxillary process andnas, 1997).
have verified the conclusions of Lumdsen and Davies
(1983, 1986). As described, when trigeminal ganglia areResults
cultured with target maxillary processes, profuse and
directed outgrowth of neurites elicited by the ganglia isStage Specificity of Maxillary Factor Activity
As a first step toward identifying Maxillary Factor, we directed toward the target (Figures 1B, 1E, 1H, 1K, and
1N). The effect appeared to be somewhat more robustreproduced the in vitro assay previously used to define
and characterize this activity in the mouse. The time in our hands, since we saw outgrowth in essentially
Maxillary Factor Is Composed of NT-3 and BDNF
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Figure 2. BDNF, NT-3, and NT-4/5 Are Candidate Mediators of Maxillary Factor Activity
(A±E) Effects of BDNF (A), NT-3 (B), NT-4/5 (C), or NGF (D and E) (all tested at 10 ng/ml) on stage 17 (A±D) or stage 18 (E) trigeminal ganglia
after 48 hr in culture. BDNF, NT-3, and NT-4/5 can each elicit axon outgrowth at the earliest stages of trigeminal axon development (shown
for stage 17 [A±C]). In contrast, NGF only acquires this ability during stage 18 (D and E).
(F±J) Expression of mRNAs for BDNF (F), NT-3 (G), NT-4/5 (H), and NGF (I and J) visualized by RNA in situ hybridization of transverse sections
through the region of the trigeminal±maxillary projection in stage 17 (F±I) or stage 18 (J) mouse embryos. BDNF, NT-3, and NT-4/5 mRNAs
are each expressed in the epithelium of the stage 17 maxillary process. BDNF and NT-3 are also expressed in the maxillary mesenchyme.
NGF expression is not detectable in the maxillary process until stage 18. Abbreviations: TG, trigeminal ganglion; mx, maxillary process; and
NT, neural tube.
Scale bar, 250 mm (A±E) and 500 mm (F±I).
100% of the cases, compared with the z54%±63% rate been identified at the time those experiments were per-
formed, and their involvement had not been tested. Later(depending on age) previously reported (Lumsden and
Davies, 1983, 1986). Minor differences in culture condi- experiments, however, showed that all three of these
factors are expressed in trigeminal target fields (thoughtions (see Experimental Procedures) may account for
this slight difference. their precise spatial distributions were not determined)
(Arumae et al., 1993; Buchman and Davies, 1993) andAs first concluded by Lumsden and Davies (1983,
1986), we found that target-derived NGF cannot make that trigeminal neurons are responsive to these factors
during these stages, at least in some assays (such asa contribution to the activity until around E11.0 (stage
18), since trigeminal axons are not responsive to NGF survival assays; Buchman and Davies, 1993). To test
the possible involvement of BDNF, NT-3, and NT-4/5 toat stage 17 (Figure 2D) but are at stage 18 (Figure 2E),
and since NGF mRNA is not detectable in the target Maxillary Factor activity, we examined their ability to
elicit axonal outgrowth from whole trigeminal ganglia inepithelium at stage 17 but is at stage 18 (Figures 2I and
2J). Thus, NGF responsiveness and expression begin the collagen gel assay at developmental stages in which
Maxillary Factor is active. Trigeminal neurons were in-concomitant with the arrival of the first trigeminal axons
at their target epithelia during stage 18. Consistent with deed found to respond to uniform concentrations of all
three factors with profuse but nondirected outgrowth atthis, antibodies to NGF have little or no effect on out-
growth elicited at stage 16, 17, or 18 but partially block the relevant stages (stages 16 and 18, data not shown;
stage 17, Figures 2A±2D). Also consistent with a possi-the activity at stage 19 and completely block it at stage
20 (Figures 1C, 1F, 1I, 1L, and 1O). Our results therefore ble involvement of these factors was our finding that,
unlike NGF, mRNA for each of the other three neuro-fully support the conclusions of Lumsden and Davies
(1983, 1986) that during the period of trigeminal axon trophins is present in the epithelium of the maxillary
process tissue at stage 17, when trigeminal axons aregrowth to the target, the chemotropic activity of the
target is due to a factor, Maxillary Factor, that is distinct navigating to their target epithelia (Figures 2F±2I). In
addition, however, mRNA for BDNF and NT-3 was alsofrom NGF and that after arrival of the axons, Maxillary
Factor activity is downregulated, while the contribution found in the mesenchyme of the maxillary process at
stage 17 (Figures 2F and 2G), which appears at oddsof NGF increases. Maxillary Factor is therefore a candi-
date for attracting the axons during their initial growth with the description of Maxillary Factor activity as being
purely epithelial in origin (Lumsden and Davies, 1986).to the target.
Neurotrophins Are Candidates for Maxillary Factor NT-3 and BDNF Account for Maxillary Factor
Activity In VitroAlthough NGF had been excluded as a candidate for
Maxillary Factor, the other members of the neurotrophin To test directly whether BDNF, NT-3, and NT-4/5 con-
tribute to Maxillary Factor activity in the in vitro coculturefamily of molecules (BDNF, NT-3, and NT-4/5) had not
Neuron
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Figure 3. NT-3 and BDNF Constitute the Major and Minor Components of Maxillary Factor Activity
(A±I) Cocultures of trigeminal ganglia (right in each panel) and maxillary process tissue (left in each panel) from stage 18 (A±D) or stage 17
(F±I) embryos were performed in the presence of function-blocking reagents to test the contribution of various neurotrophins to Maxillary
Factor activity. All cultures were performed in the presence of antibodies to NGF to ensure that only Maxillary Factor activity was assayed.
Function-blocking reagents were antibodies to BDNF (B and D) or NT-3 (C and D), or the function-blocking Trk receptor ectodomain±Fc fusion
proteins TrkA±Fc (G), TrkC±Fc (H), or TrkB±Fc (I). Axonal outgrowth was visualized by staining with anti-NF-M. The inhibition of NT-3 by anti-
NT-3 antibodies or TrkC±Fc significantly reduces most axonal outgrowth directed toward the maxillary process (C and H). However, additional
inhibition of BDNF by either anti-BDNF antibodies (B) or TrkB±Fc ([I], which blocks both BDNF and NT-3) is required to completely eliminate
all Maxillary Factor activity in the assay.
(E and J) Maxillary Factor activity was quantified by blindly scoring outgrowth responses on the one-to-four ªoutgrowth scoreº scale of Figure
9 (see Experimental Procedures) by two independent observers. Axonal outgrowth under various culture conditions was represented as a
histogram of the frequency of occurrence of different outgrowth responses to those culture conditions. Maxillary Factor activity was significantly
reduced when assayed in the presence of function-blocking antibodies to NT-3 (n 5 10, p , 0.001, Mann-Whitney U test), BDNF (n 5 10,
p 5 0.002, Mann-Whitney U test), or both antibodies (n 5 10, p , 0.001, Mann-Whitney U test). In addition, outgrowth was significantly
reduced in the presence of TrkC±Fc (n 5 11, p , 0.001, Mann-Whitney U test) and TrkB±Fc (n 5 11, p , 0.001, Mann-Whitney U test) but
not TrkA±Fc (n 5 10, p . 0.75, Mann-Whitney U test).
Scale bar, 200 mm.
assay, we made use of a number of available function- on neurotrophins by virtue of their ability to bind these
factors (Shelton et al., 1995). Control experiments withblocking reagents against the neurotrophin molecules
and of mice carrying inactivating mutations in each of these reagents on stage 17 or 18 trigeminal ganglia
cultured with neurotrophins (used at 10 ng/ml) demon-the neurotrophin genes.
We first challenged the outgrowth promoted by stage strated that 1 mg/ml TrkA±Fc completely and selectively
blocked outgrowth in response to NGF but not the other17 or 18 maxillary process tissue with highly specific
neutralizing antisera directed against either BDNF or neurotrophins, and 1 mg/ml TrkC±Fc completely and
selectively blocked outgrowth in response to NT-3 butNT-3 (Ghosh et al., 1994; Cohen-Cory and Fraser, 1995).
In control experiments, we found that each antiserum not the other neurotrophins. TrkB±Fc demonstrated a
broader specificity, with 1 mg/ml blocking outgrowth inwas, as expected from its previous characterization
(Ghosh et al., 1994; Cohen-Cory and Fraser, 1995), highly response to 10 ng/ml of either BDNF or NT-4/5 com-
pletely and also blocking outgrowth in response to 2.5specific in neutralizing the outgrowth-promoting activity
of its particular antigen (10 ng/ml BDNF or NT-3, respec- ng/ml NT-3 completely, but to 10 ng/ml NT-3, only par-
tially (data not shown). The broader specificity of TrkB±Fctively) and did not inhibit the effects of the three neuro-
trophins that were not its specific antigen (also used at is expected, since TrkB binds BDNF and NT-4/5 with
high affinity and NT-3 with lower affinity (Shelton et al.,10 ng/ml; data not shown). When added to cocultures
of stage 17 or 18 trigeminal ganglia and maxillary pro- 1995). When these Trk±Fc fusion proteins were incu-
bated with stage 17 (or stage 18; data not shown) cul-cesses, the antiserum specific for NT-3 blocked the ma-
jority but not all of the Maxillary Factor activity (n 5 10, tures of trigeminal ganglia and maxillary process tissue,
TrkB±Fc (1 mg/ml) completely blocked Maxillary Factorp , 0.001; Figures 3C and 3E). The antiserum to BDNF
appeared to have a more modest effect on its own (n 5 activity (n 5 11, p , 0.001), whereas TrkC±Fc (1 mg/ml)
consistently blocked the majority but not all of the activ-10, p 5 0.002; Figures 3B and 3E). However, when this
antiserum was used in combination with the NT-3 antise- ity (n 5 11, p , 0.001; Figures 3H±3J). As expected,
TrkA±Fc (1 mg/ml) had no effect on Maxillary Factorrum, Maxillary Factor activity was essentially completely
blocked (n 5 10, p , 0.001; Figures 3D and 3E) when activity at this stage (n 5 10, p . 0.75; Figures 3G and
3J). By themselves, these experiments implicate NT-3compared with no treatment. These results suggest that
NT-3 is the major component of the outgrowth-promot- as a major component of Maxillary Factor activity, with
a possible contribution by either BDNF or NT-4/5. How-ing activity present in maxillary process tissue, with
BDNF making a minor contribution. ever, in conjunction with our results using the neutraliz-
ing antisera against NT-3 and BDNF, they serve to con-To confirm these results, we used an independent set
of blocking reagents provided by Trk receptor±ectodo- firm the interpretation that Maxillary Factor is composed
of NT-3 (as the major component) and BDNF (as themain fusions to the constant (Fc) portion of human im-
munoglobulin. These Trk±Fc fusions, or ªreceptor bod- minor component).
A final confirmation of this interpretation was obtainedies,º have been shown to have function-blocking effects
Maxillary Factor Is Composed of NT-3 and BDNF
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Figure 4. Confirmation of Maxillary Factor Identity Using Neurotrophin-Deficient Mice
Trigeminal axon outgrowth assays were performed with neurotrophin-deficient maxillary processes to confirm the contribution of NT-3 and
BDNF to Maxillary Factor activity. Explanted trigeminal ganglia from stage 18 wild-type (CD1) mice (right in each panel) were cocultured with
maxillary processes from wild-type (A, D, and G), NT-32/2 (B), BDNF2/2 (E), or NT-4/52/2 (H) mouse embryos. Wild-type embryos used as
controls (A, D, and G) were littermates of the mutant embryos used in the corresponding panels ([B], [E], and [H], respectively). Axon outgrowth
was visualized by staining with anti-NF-M. Histograms of the frequency of occurrence of axon outgrowth responses elicited by maxillary
process tissue from NT-32/2, BDNF2/2, and NT-4/52/2 embryos, compared with tissue from wild-type and heterozygous littermates, are shown
in (C), (F), and (I) respectively, using the outgrowth scale of Figure 9. Little or no Maxillary Factor activity was observed in cultures containing
maxillary processes from NT-32/2 mice (n 5 32, p , 0.001, Mann-Whitney U test [B and C]), and a modest reduction in activity was seen using
maxillary processes from BDNF2/2 mice (n 5 19, p 5 0.005, Mann-Whitney U test [E and F]) when compared with controls (A and D). No
reduction in Maxillary Factor activity was observed compared with controls in cultures with maxillary processes from NT-4/52/2 mice (n 5 19,
p . 0.70, Mann-Whitney U test [G±I]). Scale bar, 200 mm.
by assaying for Maxillary Factor, using maxillary pro- activity and BDNF as a minor component. In fact, similar
amounts of outgrowth were observed in response tocess tissue from NT-3-deficient, BDNF-deficient, or NT-
4/5-deficient mouse embryos. These experiments were maxillary processes from both BDNF1/2 and BDNF2/2
animals, indicating that the loss of a single copy of theperformed with wild-type trigeminal ganglia (obtained
from CD1 mice) to eliminate potential complications sur- BDNF gene reduces the level of BDNF secreted to below
threshold for detection in the assay, again consistentrounding the survival of trigeminal neurons in these mu-
tant mouse backgrounds (Farinas et al., 1994; Jones et with the idea that BDNF is a minor contributor to Maxil-
lary Factor activity. In contrast, the loss of two copiesal., 1994; Liu et al., 1995). Consistent with the results
using function-blocking reagents, maxillary process tis- of the NT-3 gene caused a greater reduction of Maxillary
Factor activity than the loss of one copy of the gene,sue from NT-32/2 embryos elicited very little outgrowth
compared with tissue obtained from wild-type lit- consistent with NT-3 contributing most of the Maxillary
Factor activity.termates (n 5 32, p , 0.001; Figures 4A±4C), confirming
NT-3 as the major component of Maxillary Factor activ-
ity. Maxillary process tissue from BDNF2/2 animals dis- Maxillary Factor Activity in Maxillary Mesenchyme
and in the Hyoid Process?played only slightly less activity than that of wild-type
littermates (n 5 19, p 5 0.005; Figures 4D±4F). As ex- The identification of BDNF and NT-3 as the components
of Maxillary Factor activity was puzzling in one respect,pected, activity in maxillary process tissue from NT-
4/52/2 animals showed no difference compared with tis- since mRNAs for the factors are expressed in the mesen-
chyme of the maxillary process (Figures 2F and 2G), yetsue from wild-type littermates (n 5 19, p . 0.70; Figures
4G±4I). These results are consistent with the identifica- Maxillary Factor activity had previously been described
as primarily or exclusively epithelial in origin (Lumsdention of NT-3 as the major component of Maxillary Factor
Neuron
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Figure 5. BDNF and NT-3 Are Differentially
Expressed in Trigeminal Target Tissues
The expression of BDNF and NT-3 mRNAs
was compared by in situ hybridization on
semiadjacent mouse embryo sections at de-
velopmental stages relevant to Maxillary Fac-
tor activity (stage 16 [A±F]; stage 17 [G, H, J,
and K]; stage 18 [I and L]). (A), (D), (G), (J),
(I), and (L) are transverse oblique sections
through the anterior maxillary process along
the trigeminal±maxillary pathway. (B) and (E)
are more posterior transverse oblique sections
incorporating the trigeminal±mandibular pro-
jection. (C), (F), (H), and (K) are parasaggital
sections through the trigeminal±ophthalmic
projection. BDNF is predominantly expressed
in the anterior maxillary process and along
the ophthalmic pathway at stages 16 and 17,
when the first trigeminal axons are migrating
to their targets (A, C, G, and H). BDNF expres-
sion is low in the mandibular and hyoid pro-
cesses (B, C, and H). In contrast, NT-3 ex-
pression is predominant in the posterior
maxillary process and in the proximal regions
of the mandibular and hyoid processes (E, F,
and K). NT-3 is expressed at lower levels in
the anterior maxillary process and along the
ophthalmic pathway (D, F, and K). NT-3 ex-
pression in the anterior maxillary process be-
comes progressively stronger as develop-
ment proceeds (stages 16, 17, and 18 [D, J,
and L]). BDNF expression in the anterior max-
illary process is first detected proximal to the
trigeminal ganglion (stage 16 [A]) and then
progresses out to the periphery as develop-
ment progresses (stage 18 [I]). By stage 20,
the majority of BDNF expression is in the sub-
epithelial mesenchyme of the maxillary pro-
cess (data not shown). Abbreviations: mx,
maxillary process; md, mandibular process;
op, ophthalmic projection; oto, otocyst; hy,
hyoid process; and TG, trigeminal ganglion.
Scale bar, 500 mm.
and Davies, 1986). To address this apparent inconsis- expression in the anterior maxillary process increases as
development proceeds (compare Figures 5J and 5L). Intency in more detail, we first performed a detailed exami-
nation of the expression of these factors by mRNA in addition, the mesenchymal expression of BDNF appears
to progress from the mesenchyme more proximal to thesitu hybridization. Expression was examined from stage
15 (E9.5) to stage 19 (E11.5) in tissues of the maxillary, trigeminal ganglion (stage 16; Figure 5A) to the mesen-
chyme adjacent to the epithelium (stages 17, 18, 19;mandibular, and hyoid processes. BDNF expression
was detected in maxillary process mesenchyme, the Figures 5G and 5I; data not shown). This progression
of BDNF expression appears to correlate roughly withfirst pharyngeal pouch, the lining of the pharyngeal en-
doderm, and the otocyst at all stages examined (Figures the progression of axon growth into the target field. At
the developmental stages studied, NT-4/5 expression5A±5C and 5G±5I; data not shown). Interestingly, BDNF
expression was more restricted to the ophthalmic and was only observed in the epithelium (data not shown).
This expression analysis confirmed the expression ofanterior maxillary mesenchyme as compared with the
mesenchyme of the mandibular and hyoid processes BDNF and NT-3 in maxillary process mesenchyme and
also suggested that the relative contributions of the two(Figures 5C and 5H, and compare Figures 5A and 5B).
NT-3 expression was detected in the mesenchyme and factors might vary with developmental stage and be
different for different branches of the trigeminal gan-epithelium of the maxillary, mandibular, and hyoid pro-
cesses and in the otocyst (Figures 5D±5F and 5J±5L). glion. In the maxillary process, NT-3 expression in-
creases relative to BDNF expression between stagesHowever, NT-3 expression was significantly stronger in
the posterior maxillary mesenchyme and the proximal 16 and 18, suggesting that BDNF might play a more
prominent role at earlier stages. In the mandibularmandibular and hyoid processes relative to the anterior
maxillary or ophthalmic pathway mesenchyme (Figures process, NT-3 appears significantly more abundant than
BDNF at all stages, suggesting that it might account for5F and 5K, and compare Figures 5D and 5E). NT-3
Maxillary Factor Is Composed of NT-3 and BDNF
171
Figure 6. NT-3 Expression Correlates with Maxillary Factor Activity in the Hyoid Process
(A±D) The relationship of BDNF and NT-3 expression to the regional specificity of Maxillary Factor was investigated by RNA in situ hybridization
on transverse sections of stage 17 mouse embryos (C and D). BDNF is expressed strongly in the otocyst and pharyngeal endoderm but is
absent from the epithelium and mesenchyme of the hyoid process (C). In contrast, NT-3 is expressed in the epithelium and mesenchyme of
the hyoid process, in addition to the otocyst (D). NT-3 expression is significantly stronger in the proximal regions of the hyoid process (pHy)
than in the distal portion (dHy). This differential level of NT-3 mRNA expression in the hyoid process correlates with an increased ability to
detect Maxillary Factor activity in proximal (B) but not distal (A) hyoid tissue in coculture assays with trigeminal ganglia.
(E) Histogram comparing the frequency of occurrence of axon outgrowth elicited by proximal and distal hyoid tissue responses (using the
outgrowth scale of Figure 9). Proximal hyoid (n 5 10) tissue is significantly better at eliciting outgrowth than distal hyoid (n 5 10, p 5 0.01,
Mann-Whitney U test).
Scale bar, 200 mm (A and B) and 500 mm (C and D).
even more of the Maxillary Factor activity detected in Davies did in fact use the distal hyoid in their experi-
ments (A. Lumsden and A. Davies, personal communi-that tissue (Lumsden and Davies, 1983). Conversely,
BDNF is enriched relative to NT-3 in the mesenchyme cation).
of the ophthalmic branch, suggesting that it might
contribute more to the activity that is predicted to be Expression of NT-3 and BDNF Is Lost upon Separation
of Epithelium and Mesenchymeassociated with that mesenchyme.
Lumsden and Davies (1986) had previously used the The finding that Maxillary Factor is composed of BDNF
and NT-3 was puzzling in light of the previously reportedhyoid process, an adjoining cutaneous target tissue not
normally innervated by trigeminal axons, as a nonspe- epithelial specificity of Maxillary Factor activity (Lums-
den and Davies, 1986). In those experiments, coculturecific control tissue and had described the hyoid process
as being devoid of activity. Another apparent paradox of isolated first branchial arch epithelium or mesen-
chyme with trigeminal ganglia resulted in axonal out-was therefore raised by our initial finding that NT-3
mRNA is expressed in the hyoid process. However, in growth directed only toward epithelial tissue and never
toward mesenchyme. The finding that BDNF and NT-3transverse sections, we observed a gradient of NT-3
transcripts, high in the proximal portion and very low in are expressed in the mesenchyme at similar or greater
levels than in the epithelium did not readily fit with thosethe distal portion of the hyoid process (Figures 6C and
6D). Consistent with this observation, we found that, at observations.
We therefore sought to repeat those experiments,stage 17, explants of the proximal hyoid, but not the
distal hyoid (n 5 10, Figures 6A and 6E; n 5 10, p 5 which involved digesting maxillary process tissue with
a protease, such as trypsin, pancreatin, or dispase and0.01, Figures 6B and 6E), could elicit outgrowth of axons
from trigeminal ganglia, albeit at a low level. These find- separating the epithelium from the mesenchyme prior to
culture with the trigeminal ganglion. When we attemptedings therefore resolve the paradox, as Lumsden and
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Figure 7. Surface Ectoderm Maintains the
Expression of NT-3, but Not BDNF, in Under-
lying Mesenchyme
(A±F) The maintenance of NT-3 expression in
cultures of mandibular process was exam-
ined, using NT-32/2 embryos, which express
b-galactosidase under the control of the NT-3
promoter (Farinas et al., 1994). (Similar results
were obtained with NT-31/2 embryos and with
maxillary process tissue.) Whole mandibular
process (A and B), mandibular mesenchyme
(C and D), or mandibular epithelium (E and F)
were either fixed immediately (A, C, and E) or
cultured for 24 hr (B, D, and F) in collagen
matrices under conditions identical to those
for Maxillary Factor assays. Mandibular epi-
thelium and mesenchyme were mechanically
separated following enzymatic digestion with
pancreatin. NT-3 expression was maintained
in whole mandibular process tissue after 24
hr of culture (B). In contrast, NT-3 expression
was nearly abolished in isolated mesen-
chyme (D) or epithelium (F) following 24 hr of
culture. Epithelial±mesenchymal interactions
also appear to be required for growth of the
mandibular process tissue in these assays
(compare [A] and [B] with [C] and [D]). As
illustrated in (F), in such experiments a por-
tion of the epithelial tissue often becomes
necrotic, with the remainder surviving the cul-
ture period.
(G±I). The expression of NT-3 and BDNF mRNAs in whole stage 18 first branchial arch tissue (squares) or in isolated first branchial arch
mesenchyme (circles) was quantified by competitive RT-PCR, using freshly isolated tissue or tissue that had been cultured for 24 hr as
described above. Plots of the ratio of competitor product to endogenous cDNA product as a function of the number of molecules of added
competitor are shown for NT-3 (G), BDNF (H), and b-actin (I). The plot in (G) indicates a 45-fold decrease in absolute NT-3 mRNA levels in
cultured first arch mesenchyme compared with cultured whole first arch tissue. After normalization to the levels of b-actin in the tissues (I),
a 17-fold decrease in NT-3 levels is observed. This effect is not due to the presence of the epithelial tissue, since a 15-fold decrease in NT-3
levels (after normalization) was observed in cultured mesenchyme relative to the level in freshly isolated mesenchyme (data not shown). BDNF
mRNA levels (normalized to b-actin levels) in first arch mesenchyme appear to decrease slightly upon culture compared with cultured whole
first arch tissue (1.4-fold [H]) or freshly isolated mesenchyme (2.5-fold; data not shown). In an independent experiment, NT-3 and BDNF levels
in the mesenchyme decreased 16-fold and 2.6-fold relative to whole first arch tissue (data not shown). Thus, mesenchymal expression of
NT-3, but not BDNF, mRNA appears to be maintained by interactions with the epithelium.
Scale bar, 200 mm (A±F).
such separations, under conditions in which the epithe- remained contaminated with a layer of mesenchyme
during the dissociation procedure (data not shown). Thislium and mesenchyme were cleanly separated, to our
surprise we found that neither tissue had activity in the raised the possibility that an interaction between epithe-
lium and mesenchyme may be required to maintain theassay. This did not appear to result from some nonspe-
cific action of the proteases, since in control experi- expression of Maxillary Factor activity (i.e., NT-3 and
BDNF) during the culture period.ments in which maxillary process tissue was treated
with protease but the epithelium and mesenchyme were To test this hypothesis, we took advantage of the fact
that the targeting construct used to inactivate the NT-3left in contact, we observed the expected Maxillary Fac-
tor activity (data not shown). allele in the NT-3-deficient mice directed expression
of b-galactosidase under control of the NT-3 promoterIt is not certain what accounts for the difference be-
tween our results and those of previous investigators. region (Farinas et al., 1994). When whole maxillary or
mandibular processes (stage 18) were cultured for 24It is possible that they were better able to maintain the
health and integrity of the isolated tissues than we were hr (one half of the standard culture period), the expres-
sion of b-galactosidase was maintained in the tissue(see below). It is also worth noting that the apparent
discrepancy may not be as great as it seems, since (compare Figures 7A and 7B; the effect is illustrated
here for experiments using mandibular process tissuealthough they reported growth exclusively toward the
isolated epithelium, outgrowth was observed only in because of the high level of NT-3 expression in that
tissue, but maxillary process tissue gave identical re-28% of such cocultures at E11 and in 15% at E10 (Lums-
den and Davies, 1986). sults; data not shown). In contrast, when the isolated
epithelium or mesenchyme from enzymatically digestedIn addition, in the course of these experiments, we
found a clue as to why activity was lost in the tissues, tissue was cultured for 24 hr, b-galactosidase expres-
sion was routinely lost (compare Figures 7C and 7E withat least in our hands. Although we never observed out-
growth toward isolated mesenchyme under any circum- Figures 7D and 7F). These results were quantified by
quantitative RT-PCR using wild-type tissue. An z16-stances, we did observe that outgrowth occurred to-
ward isolated epithelium in cases in which the epithelium fold reduction in NT-3 expression (relative to b-actin;
Maxillary Factor Is Composed of NT-3 and BDNF
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Figure 8. Trigeminal Axon Projections Appear Normal in BDNF2/2;NT-32/2 Double Mutant Embryos
Trigeminal projections at stage 19 (E11.5) in wild-type (A), BDNF2/2 (B), NT-32/2 (C), or BDNF2/2;NT-32/2 mouse embryos stained for neurofilament
(NF-M) expression. The branches of the trigeminal ganglion are labeled in (A) (op, ophthalmic; mx, maxillary; and md, mandibular). The
developmental timing and accuracy of innervation of trigeminal target tissues appeared unaffected in the mutant mouse embryos when
compared with wild-type littermates.
Figure 7I) occurred when mesenchyme was cultured for et al., 1994a, 1994b). Therefore, we examined mouse
embryos deficient in both BDNF and NT-3 for defects24 hr (Figure 7G). Interestingly, no significant reduction
in BDNF expression relative to b-actin was observed in developmental timing or misrouting of trigeminal axon
projections. At stage 17 (data not shown) and stage 19upon culture of isolated mesenchyme (Figure 7H). De-
spite this maintenance of BDNF transcripts relative to (Figures 8A±8D), trigeminal sensory axons in BDNF2/2;
NT-32/2 mice invaded the maxillary process mesen-b-actin, the total absence of detectable Maxillary Factor
activity in isolated mesenchyme may be due to the re- chyme without apparent defects or delays. The trigemi-
nal±maxillary projection in these mice was indistinguish-duction in the absolute level of BDNF activity (already
the minor component) that results from the absence of able from that of wild-type embryos (n 5 4 mutant and
wild-type stage 17 embryos and 6 mutant and wild-typegrowth of the mesenchymal tissue when separated from
its epithelium (compare Figures 7A and 7B with Figures stage 19 embryos), at least at this level of resolution.
The same was true of trigeminal axonal trajectories in7C and 7D). These results provide support for the hy-
pothesis that an epithelial±mesenchymal interaction is NT-32/2;NT-4/52/2 double knockout mice (at stage 18;
data not shown). Because of poor breeding of the mu-required to maintain expression of NT-3, but not BDNF,
in first branchial arch tissue, which, in conjunction with tants, we were not able to generate triple mutant em-
bryos in BDNF, NT-3, or NT-4/5, despite repeated at-the absence of growth of the mesenchymal tissue, would
explain the absence of Maxillary Factor activity ob- tempts.
served with epithelium and mesenchyme cultured alone.
It seems likely that the absence of activity in mesen- Discussion
chyme observed by Lumsden and Davies is also ex-
plained by this requirement. Their finding that activity Previous studies identified a chemoattractant activity,
Maxillary Factor, secreted by the maxillary and mandib-could be observed in some cases in isolated epithelium
that was completely cleared of mesenchyme (A. Lums- ular processes, that can attract developing trigeminal
sensory axons in cell culture. Here, we show that Maxil-den and A. Davies, personal communication) is presum-
ably due to some difference in their culture conditions, lary Factor activity is made up of a combination of NT-3
and BDNF, two members of the neurotrophin family.compared with ours, that allowed epitheliumÐbut not
mesenchymeÐto retain some expression of BDNF and/ NT-3 and BDNF are expressed at sufficient levels within
trigeminal target tissues to elicit directional outgrowthor NT-3.
of trigeminal axons in vitro at developmental stages in
which these axons are growing to their target in vivo.Trigeminal Axon Guidance in Double Knockout
Mouse Embryos NT-3 is the major component of the activity from maxil-
lary process, and BDNF the minor component, an obser-The expression patterns of BDNF and NT-3 did not sug-
gest roles as target-derived chemotropic factors guiding vation that is consistent with the findings by quantitative
Northern analysis that NT-3 transcripts are significantlythe initial growth of trigeminal axons into the maxillary
process. However, it remained possible that they could more abundant than BDNF transcripts in maxillary tissue
at E9.5 and E10 (Buchman and Davies, 1993). However,contribute to the guidance of trigeminal axons by acting
as permissive molecules along the pathway of the tri- NT-3 and BDNF mRNAs are expressed by both the path-
way mesenchyme and the target epithelia of trigeminalgeminal axon projections. Previous experiments failed
to observe defects in the guidance of trigeminal axons neurons, suggesting that they are not likely to provide
directional cues in vivo. Indeed, the initial trajectory ofin either BDNF2/2 or NT-32/2 mouse embryos (Ernfors
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trigeminal axons to their targets in mice deficient for in isolated mesenchyme. The absence of detectable ac-
tivity is, however, likely to be explained by the fact thatNT-3 and BDNF appears normal. While a direct role
for neurotrophins in the initial guidance of trigeminal the intact maxillary process increases in size during cul-
ture, whereas the isolated maxillary process does not,sensory axons into the maxillary process in vivo seems
unlikely, these factors might nonetheless promote or and even shows a small degree of cell death (Figure 7;
data not shown), presumably due to the existence ofreinforce the growth of these axons into trigeminal target
tissues. Our results also do not exclude a possible tropic proliferative and survival signals in the epithelium for
the mesenchyme. As a consequence, the absolute amountrole for these factors at later stages.
of BDNF expressed by cultured isolated mesenchyme
is less than that in cultured intact maxillary processesResolution of Apparent Discrepancies between
(Figure 7H) and is presumably below threshold for detec-Sites of Expression of Maxillary
tion in the assay. Indeed, analysis of BDNF1/2 andFactor and of Neurotrophins
BDNF2/2 embryos showed that a 2-fold decrease inPrevious studies (Lumsden and Davies, 1983) identified
BDNF expression eliminates detectable BDNF activity,Maxillary Factor as an in vitro chemotropic guidance
consistent with BDNF expression being at threshold foractivity for trigeminal sensory axons that is active during
detection (see Results).the primary stages of axon outgrowth and immunologi-
A minor difference between our study and that ofcally distinct from NGF. We have verified these conclu-
Lumsden and Davies (1986) is that they observed somesions and used this in vitro assay to identify Maxillary
Maxillary Factor activity in isolated epithelium, whereasFactor activity in the maxillary process as NT-3 (the
we did not, except in a few cases in which a layer ofmajor component) and BDNF (the minor component).
mesenchyme remained attached to the epithelium. It isThis identification was initially surprising because of the
possible that these authors used larger pieces of epithe-reported epithelial specificity of the activity (Lumsden
lium or that their culture conditions were better able toand Davies, 1986), which contrasts with the distribution
support the growth of the epithelium or its expression ofof the factors. Previous studies analyzing the expression
neurotrophins. Indeed, they observed Maxillary Factorof these molecules by in situ hybridization (Arumae et
activity in only a minority (28%) of isolated epithelia, andal., 1993) and Northern blot (Buchman and Davies, 1993)
they also noted that activity was seen more frequentlyobserved both BDNF and NT-3 expressed strongly in
when the epithelium contacted the plastic substrate andthe mesenchyme of first branchial arch tissues. We have
flattened out (Lumsden and Davies, 1986), consistentconfirmed and extended these conclusions by showing
with the idea that the level of Maxillary Factor activitythat NT-3, NT-4/5, and BDNF mRNAs are expressed in
was around threshold for detection in the assay and wasthe epithelium, and NT-3 and BDNF mRNAs are ex-
dependent on precise details of the culture conditions.pressed in the mesenchyme of the branchial arches at
A further apparent discrepancy is that NT-3 is alsoall stages of the growth of trigeminal sensory axons to
expressed in the second branchial arch (or hyoid pro-their targets. While these in situ hybridization studies
cess; Buchman and Davies, 1993; Figure 6), whereasdemonstrate the mesenchymal expression of these fac-
Maxillary Factor activity was not detected in this tissuetors, the epithelial specificity of Maxillary Factor expres-
(Lumsden and Davies, 1986). However, NT-3 expressionsion was concluded from in vitro culture of isolated
in the hyoid process, as in the mandibular arch, is origi-maxillary epithelium and mesenchyme with trigeminal
nally concentrated in the proximal portion of the hyoid.ganglia, in which trigeminal axons were observed to
When proximal versus distal portions of the processgrow toward the epithelium but never the mesenchyme
were tested for Maxillary Factor activity at early stages(Lumsden and Davies, 1986).
(stage 17), activity was found only in the proximal tissue.This apparent discrepancy is explained by our finding
Lumsden and Davies (1986) did in fact use the distalthat expression of NT-3 in the mesenchyme requires
hyoid process in their experiments (A. Lumsden and A.signaling from the overlying epithelium. Thus, the level
Davies, personal communication), thus explaining whyof NT-3-dependent b-galactosidase activity (in mesen-
they did not detect activity.chyme from the NT-3 knockout/reporter strain) declined
Taken together, the precise details of neurotrophindramatically upon culture of isolated mesenchyme. Sim-
expression patterns and their dependence on epithe-ilarly, the number of NT-3, but not BDNF, transcripts
lium±mesenchymal interactions make it possible to rec-declined z16-fold relative to control b-actin transcripts
oncile apparent inconsistencies between the sites ofwhen wild-type first branchial arch mesenchyme was
expression of Maxillary Factor and the sites of NT-3 andcultured without epithelium, as measured by quantita-
BDNF expression.tive RT-PCR. A similar dependence of mesenchymal
expression of NT-3 on signals from the overlying epithe-
lium was independently discovered in the embryonic Neurotrophins and Trigeminal Axon Guidance
The expression of NT-3 and BDNF in the mesenchymemouse limb by Patapoutian et al. (1999), who have pro-
vided evidence that these interactions may be mediated along the entire pathway navigated by trigeminal sen-
sory axons has implications for their roles as putativeby member(s) of the Wnt family of signaling molecules.
Since BDNF contributes, albeit in a minor way, to the axon guidance molecules. These expression patterns
do not obviously suggest a role in providing directionalMaxillary Factor activity in intact maxillary processes,
and since BDNF transcripts do not decline relative to information to guide axons to epithelial targets. Instead,
they most likely indicate a contribution to a permissiveb-actin transcripts in cultured isolated mesenchyme, it
might have been expected that some residual Maxillary substrate, promoting the general growth of trigeminal
axons, and with other cues imparting directionality.Factor activity, mediated by BDNF, would be detectable
Maxillary Factor Is Composed of NT-3 and BDNF
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Since we have only examined mRNA, not protein expres- is modulated differentially by BDNF (which is relatively
sion, we cannot entirely exclude the presence of a neu- enriched in the maxillary process) and NT-3 (which is
rotrophin protein gradient. Nonetheless, our finding that relatively enriched in the mandibular process).
mice lacking NT-3 and BDNF function do not display Finally, the analysis of NT-3 and of trkB and trkC
obvious defects in the guidance of trigeminal sensory knockout mice has shown that NT-3, and almost cer-
axons speaks against a role for these neurotrophins in tainly BDNF as well, functions to support the survival
providing directional information. It could be argued that of trigeminal neurons from early stages (soon after, or
NT-4/5, which is not a component of the in vitro±defined possibly even before they reach the vicinity of their dif-
Maxillary Factor activity but which is restricted to the ferentiating target fields) until about E13 (stage 21), when
epithelium, might be present in a gradient that can guide they become dependent for their survival on NGF (Da-
the axons locally in both wild-type and NT-3/BDNF vies et al., 1995; ElShamy and Ernfors, 1996; Pinon et
double knockout animals. However, no guidance de- al., 1996; Wilkinson et al., 1996). It is conceivable that
fects were seen in trigeminal projections in NT-4/52/2 or this is the major or even the only role of the BDNF and
NT-32/2;NT-4/52/2 animals, again arguing against an im- NT-3 in the early development of trigeminal sensory
portant guidance role. In fact, since BDNF is expressed neurons and that their in vitro functions in axon guidance
more strongly in the mesenchyme than in the epithelium do not have an in vivo correlate.
in NT-32/2;NT-4/52/2 animals, one would predict, if any- Currently, the factors that direct the branch-specific
thing, the presence of a neurotrophin countergradient, guidance of trigeminal sensory axons are unknown. In
higher in the mesenchyme than the epithelium. The ab- the presence of function-blocking reagents for BDNF
sence of observable defects in these animals thus again and NT-3, no outgrowth is observed toward the maxillary
argues against an involvement of neurotrophins in pro- process, and thus, there is no evidence at present for
viding guidance information to direct axons to the epi- the existence of an additional chemoattractant made by
thelium. the maxillary process. One caveat to this conclusion is
One caveat to this conclusion is that we cannot ex- that such a chemoattractant might exist, but may have
clude the presence of subtle defects not detectable with eluded detection, if it is dependent for its expression or
the general axonal marker (anti-neurofilament) used to action on the presence of neurotrophins. Further studies
label axons here. In addition, even if the major role of will be required to determine (1) whether there is in fact
neurotrophins is to promote growth in each of the three another nonneurotrophin chemoattractant and (2) what
branches of the trigeminal system, they could in princi- other cues function alone or with the neurotrophins to
ple play an instructive role in the selection of these direct trigeminal axon growth.
branches by axons, since NT-3 is enriched in the man-
dibular pathway, and BDNF in the ophthalmic and maxil- Neurotrophins as Axon Guidance Molecules
lary pathways. Thus, if different subpopulations of tri- Although the evidence does not yet support a role for
geminal sensory axons are differentially responsive to neurotrophins in guiding developing trigeminal axons to
BDNF and NT-3, this could help dictate branch selec- their epithelial targets, this does not exclude a possible
tion. The absence of markers to distinguish the different
role for neurotrophins in guiding other classes of axons.
classes of trigeminal sensory axons precludes an exami-
The permissive or outgrowth-promoting property of
nation of this possibility at this time. Finally, our results
neurotrophins observed in vitro may reflect a role for
also do not exclude a possible involvement of these
neurotrophins in enabling axonal invasion of certain tar-factors in guidance at later stages, after E11.5 (the stage
get fields. One clear case of this is provided by theat which the knockout animals were studied), when indi-
sympathetic innervation of the pineal gland, which isvidual axons leave the main fascicles to seek out individ-
controlled by NT-3. In NT-32/2 mice, sympathetic fibersual targets.
approach the target but fail to invade it, and this defectWhile we have suggested a role for BDNF and NT-3
can be rescued by infusion of exogenous NT-3 (ElShamyin providing a permissive substrate for growth, the ab-
et al., 1996). Invasion of other targets has similarly beensence of defects in the knockout animals indicates that
shown to require an increased gradient of NGF (Hoyleother growth permissive cues must be present in these
et al., 1993). In addition, Lentz et al. (1999) have pro-animals, which must be sufficient for trigeminal axon
posed that neurotrophins may function to support thegrowth. Identification of these cues and disruption of
growth of sensory axons in order to keep pace with thetheir function will be necessary to determine whether
overall growth of the embryo. Furthermore, the abilityneurotrophins play a functionally redundant role with
of neurotrophins to function as chemoattractants whenthose cues in stimulating the growth of trigeminal axons
applied exogenously to axons in vitro (Gundersen andto their targets.
Barrett, 1979; Ming et al., 1997; Song et al., 1997, 1998)Neurotrophins might also play an indirect role in guid-
or in vivo (Menesini-Chen et al., 1978) is likely to reflectance by modulating responses to other guidance cues.
a role for these factors within target fields in attractingPrecedents for this are provided by the findings that the
terminal axonal branches to regions of higher neuro-sensitivity of chick sensory neurons to Sema3A in vitro
trophin expression, as in the case of the attraction ofis increased rapidly by exposure to BDNF and de-
sensory axon branches by denervated patches of skin,creased by exposure to NGF (Tuttle and O'Leary, 1998),
in which NGF expression is upregulated (e.g., Diamondwhereas prior exposure of cerebellar neurons to BDNF
et al., 1987). Whether this chemoattractant ability re-makes these neurons impervious to the inhibitory effects
flects a role in providing directional information for anyof myelin associated glycoprotein and myelin (Cai et al.,
class of developing axons en route to their targets re-1999). It is conceivable, therefore, that the sensitivity of
mandibular and maxillary branch axons to repellent(s) mains, however, to be determined.
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Experimental Procedures AGGAG-39, BDNFwt/mut: (IMR133) 59-ATGAAAGAAGTAAACGTC
CAC-39 (wt, 276 bp), BDNFmut: (IMR132) 59-GGGAACTTCCTGAC
TAGGGG-39 (mut, 280 bp); NT-4/5wt: 59-CAGTGTGCGATGCAGTGAExplant Culture
Maxillary Factor assays were performed essentially as described GTG-39, 59-CTTACATTCTGAGAGCCAGTGC-39 (229 bp); NT-4/5mut:
(PGK1) 59-GTTCTCCTCTTCCTCATCTCC-39, (NEO1) 59-CTTCAGTGpreviously (Lumsden and Davies, 1983). Briefly, mouse embryos
were obtained from overnight matings of CD1 mice, and the stage ACAACGTCGAGC-39 (311 bp). The PCR cycles for each gene's
primer pairs were as follows. NT-3 (30 cycles): 948C for 1 min, 658Cof development was determined by the criteria of Theiler (Theiler,
1989). Electrolytically sharpened tungsten needles were used to for 1 min, and 728C for 1 min; BDNF (35 cycles): 948C C for 1 min,
508C for 1 min, and 728C for 1 min; and NT-4/5 (35 cycles): 948C fordissect trigemnal ganglia and maxillary, mandibular, and hyoid pro-
cesses in L15 medium (GIBCO). Tissues were embedded in rat tail 1 min, 598C for 1 min, and 728C for 1 min.
collagen and cultured for 48 hr at 378C in F12K medium (GIBCO)
supplemented with N3 components (Romijn et al., 1981) and 2% RNA Expression Analysis
RNA in situ hybridization was performed as described previouslyheat-inactivated fetal bovine serum (FBS). At 14±16 hr of incubation,
cytosine arabinoside (Sigma) was added to cultures at 1025 M to (Fan and Tessier-Lavigne, 1994). The 35S-labeled riboprobes were
generated from the genes for mouse NGF (nucleotides 66±859; Scottprevent nonneuronal cells within the ganglia from migrating between
the ganglion and target tissue. et al., 1983), rat BDNF (nucleotides 681±1141; Phillips et al., 1990),
rat NT-3 (nucleotides 355±828; Phillips et al., 1990), and rat NT-4/5Neurotrophins were used at 10 ng/ml. A function-blocking anti-
body to NGF (a gift of W. Mobley, Stanford University) was used at (nucleotides 48±614). Hybridizations were for 16 hr at 558C (BDNF
and NT-3) or 608C (NGF and NT-4/5). Exposure times were 4 weeks,1:4000. Function-blocking antibodies to NT-3 and BDNF (a gift of
J. Carnahan, Amgen) were used at 1:500 and 1:333, respectively. 8 weeks, 6 weeks, and 4 weeks for NGF, BDNF, NT-3, and NT-4/5,
respectively.Trk±Fc fusion proteins (a gift of D. Shelton, Genentech) were each
used at 1 mg/ml. All function-blocking reagents could completely
block the axon outgrowth elicited by 10 ng/ml of their cognate Quantitative RT-PCR
Quantitative RT-PCR was carried out as previously described (Gil-neurotrophins on stage 18 trigeminal ganglia and were routinely
added at the beginning of the culture period. land et al., 1990; Ebens et al., 1996). In brief, first branchial arch
tissues constituting both the maxillary and mandibular processesMaxillary and mandibular processes were separated into their
component epithelia and mesenchyme by enzymatic digestion with were isolated from stage 18 mouse embryos and either frozen imme-
diately (fresh) or cultured for 24 hr in a collagen gel under Maxillary53 pancreatin (GIBCO) for 40 min on ice at 48C. Digestion was
stopped by washing the tissues in L15 plus 20% heat-inactivated Factor assay conditions (cultured). Total RNA was prepared with
TRIzol reagent (GIBCO), treated with RNAse-free DNAse I for 15 minFBS. Tissues were then embedded in collagen and frozen immedi-
ately or cultured as described above. at 378C, and repurified, and random hexamer±primed cDNA was
prepared as described (Fan and Tessier-Lavigne, 1994). cDNA prep-
arations were normalized for RNA recovery and cDNA synthesisImmunohistochemistry
efficiency by competitive amplification of mouse b-actin (primersExplant cultures were fixed with 4% paraformaldehyde (PFA) in
59-CATGGCATTGTTACCAACTGG-39, 59-TGTGGTGGTGAAGCTGTphosphate-buffered saline (PBS) for 1 hr at room temperature. Cul-
AGC-39, amplification product of 392 nucleotides). Relative NT-3tures were then washed with PBS, preincubated with PBS con-
and BDNF transcript content was determined in parallel experimentstaining 1% heat-inactivated sheep serum (Sigma) and 0.2% Triton
by competitive amplification of NT-3 (primers 59-ACTACGGCAACAGX-100 (PHT), and incubated in PHT containing the neurofilament-
AGACGCTAC-39, 59-ACAGGCTCTCACTGTCACACAC-39, product ofspecific antibody NF-M (RMO170; a gift of V. Lee, University of
200 nucleotides) and BDNF (primers 59-CCAGCAGAAAGAGTAGAGVirginia) overnight at 48C. After extensive washing, cultures were
GAG-39, 59-ATGAAAGAAGTAAACGTCCAC-39, product of 276 nucle-incubated in horse radish peroxidase± (HRP-) coupled sheep anti-
otides). Competitive amplifications involved using a constantmouse secondary antibody overnight at 48C. Cultures were then
amount of cDNA against a log dilution series of an appropriateextensively washed with PHT before development with 3,39diamino-
competitor template constructed to contain the mouse b-actin,benzidine (DAB; Sigma) in PBS at room temperature.
NT-3, or BDNF primer sequences and to yield larger products (497Whole embryos were harvested in L15 medium and fixed in PFA
nucleotides for the b-actin competition template, 287 nucleotidesfor 3 hr at room temperature. After washing with PBS, embryos were
for the NT-3 competition template, and 363 nucleotides for the BDNFdehydrated to 80% methanol, and endogenous peroxidases were
competition template). Amplifications involved 25 cycles of 948C (30quenched in 80% methanol containing 6% hydrogen peroxide for
s), 638C (1 min), and 728C (1 min) for b-actin; 948C (1 min), 658C (16 hr. Following rehydration back to PBS, embryos were preincu-
min), and 728C (1 min) for NT-3; and 948C (1 min), 508C (1 min), andbated in PHT containing 2% nonfat dried milk (PHTM) for at least
728C (1 min) for BDNF. Reaction products were separated on 2.5%2 hr and then incubated in PHTM containing NF-M at 1:500. Embryos
agarose gels, dried, and quantified with a Molecular Dynamics Phos-were then washed extensively in PHTM, incubated in HRP-coupled
phorimager.sheep anti-mouse secondary antibody at 1:500 for 6 hr, washed
again with PHT, and developed with DAB (Figure 8) or DAB con-
Acknowledgmentstaining 0.5% nickel chloride (Figure 1) in PBS at room temperature.
All procedures were at 48C unless otherwise stated.
We are grateful to A. Davies for help in establishing the MaxillaryExplant cultures of maxillary and mandibular processes from NT-3
Factor assay and to A. Davies and A. Lumsden for helpful discus-heterozygous or homozygous embryos were developed for
sions and for comments on the manuscript. Thanks also to V. Leeb-galactosidase activity following a 15 min fixation in PFA at room
temperature. Cultures were washed with PBS and developed with
1 mg/ml X-gal (Sigma) at room temperature overnight in the dark.
Animal Husbandry and Embryo Genotyping
Heterozygous mice carrying inactivating mutations in NT-3 (Farinas
et al., 1994), BDNF (Jones et al., 1994), and NT-4/5 (Liu et al., 1995)
were mated, and embryos were harvested between Theiler stages
16 and 19. The yolk sac for each embryo was used for genotyping
by PCR. Primers for PCR of the wild-type and mutant alleles for
Figure 9. Scale Used to Score the Degree of Trigeminal Axon Out-each gene and the sizes of the products are as follows: NT-3wt:
growth59-ACTACGGCAACAGAGACGCTAC-39, 59-ACAGGCTCTCACTGTCA
CACAC-39 (200 bp); NT-3mut: (PGK2) 59-GTGCCAGCGGGGCTGC Axon outgrowth from stage 18 trigeminal ganglion explants was
scored blindly by two independent observers using the one-to-fourTAAAGCGC-39, (SV40F) 59-CTGCATTCTAGTTGTGGTTTGTCCAAA
CTCATC-39 (150 bp); BDNFwt: (IMR134) 59-CCAGCAGAAAGAGTAG scale shown here.
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